Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
McKinsey
McKesson
Accenture
Johnson and Johnson
Healthtrust
Merck
Chubb
Teva

Generated: December 11, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Bupropion Hydrochloride; Naltrexone Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00129246 Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 1/Phase 2 This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.
NCT00129246 Low-Dose Naltrexone Combined With Bupropion to Stop Smoking With Less Weight Gain Completed Yale University Phase 1/Phase 2 This study will test a combination of the drugs naltrexone and bupropion with weight-concerned smokers to investigate whether or not this combination of drugs improves smoking cessation quit rates and minimizes post quit weight gain.
NCT00208169 Abilify Therapy for Reducing Comorbid Substance Abuse Completed Bristol-Myers Squibb Phase 4 It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) - Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale - Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
NCT00208169 Abilify Therapy for Reducing Comorbid Substance Abuse Completed Creighton University Phase 4 It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: - Reduction in the amount of alcohol and/or drugs used as measured by the Time Line Follow Back (TLFB) and the Addiction Severity Index (ASI) - Reduction in cravings for alcohol and drugs as measured by the Penn Alcohol Craving Scale - Reduction in symptoms of co-morbid psychiatric disorders compared to before starting aripiprazole.
NCT00364871 Efficacy and Safety Study of Combination Therapy to Treat Uncomplicated Obesity Completed Orexigen Therapeutics, Inc Phase 2 The purpose of this study is to determine the efficacy and safety of 3 combinations of naltrexone and bupropion SR compared to naltrexone alone, bupropion SR alone or placebo.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Bupropion Hydrochloride; Naltrexone Hydrochloride

Condition Name

Condition Name for Bupropion Hydrochloride; Naltrexone Hydrochloride
Intervention Trials
Obesity 17
Overweight 8
Binge-Eating Disorder 4
Nicotine Dependence 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Bupropion Hydrochloride; Naltrexone Hydrochloride
Intervention Trials
Overweight 11
Disease 6
Obesity 6
Binge-Eating Disorder 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Bupropion Hydrochloride; Naltrexone Hydrochloride

Trials by Country

Trials by Country for Bupropion Hydrochloride; Naltrexone Hydrochloride
Location Trials
United States 203
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Bupropion Hydrochloride; Naltrexone Hydrochloride
Location Trials
Connecticut 12
California 11
Texas 10
North Carolina 8
Ohio 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Bupropion Hydrochloride; Naltrexone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Bupropion Hydrochloride; Naltrexone Hydrochloride
Clinical Trial Phase Trials
Phase 4 6
Phase 3 7
Phase 2/Phase 3 5
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Bupropion Hydrochloride; Naltrexone Hydrochloride
Clinical Trial Phase Trials
Completed 18
Recruiting 8
Terminated 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Bupropion Hydrochloride; Naltrexone Hydrochloride

Sponsor Name

Sponsor Name for Bupropion Hydrochloride; Naltrexone Hydrochloride
Sponsor Trials
Orexigen Therapeutics, Inc 14
Yale University 8
National Institute on Drug Abuse (NIDA) 6
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Bupropion Hydrochloride; Naltrexone Hydrochloride
Sponsor Trials
Other 20
Industry 18
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Baxter
Medtronic
Chinese Patent Office
Argus Health
Federal Trade Commission
Fuji
McKinsey
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.